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& INTRODUCTION
In the last two decades, significant developments in
immunosuppressive therapies have provided transplant
teams with more options for the care of transplant patients,
with the promise of less toxicity and comparable or better
efficacy. There are several potential target sites for immu-
nosuppressive agents in transplantation, with examples
demonstrating both established and new agents in Figures 1
and 2. The number of available immunosuppressive agents
offers additional therapeutic strategies to provide better
patient and allograft survival. The use of these newer agents
in children has been limited in clinical studies, leading to
off-label usage in pediatric centers based on small case
studies. In addition, the long-term risks of newer immuno-
suppressive agents are not well documented and pose
several challenges for clinicians.
& ALEMTUZUMAB
Alemtuzumab, a monoclonal antibody targeting the CD52
antigen present on T and B lymphocytes, natural killer (NK)
cells, and monocytes, was first used as an induction agent
in kidney transplants by Calne et al. in 1998 (1,2). Although
not approved by the United States Food and Drug Admi-
nistration (FDA) for use in transplantation surgeries, it has
gained popularity as an induction agent (1,3,4). An
intravenous dose of 0.4-0.5 mg/kg, with a maximum dose
of 30 mg, resulted in prolonged lymphocyte depletion (5,6).
The effects of alemtuzumab include a profound depletion
of total T cells and differential recovery of CD8+ T cells, with
late and only partial recovery of the CD4+ subsets and
relative sparing of CD4+ memory cells (7-9).
Serres and colleagues prospectively characterized the T
cell subsets following lymphocyte depletion with alemtu-
zumab induction and the subsequent recovery patterns in
children. Three months following alemtuzumab induction,
both memory and naı¨ve cells were depleted to a similar
extent. Within the CD4+ memory subset, there was a slightly
greater depletion of the central memory subset (TCM)
compared with the effector memory subset (TEM), the latter
of which is thought to be involved in acute cellular rejection
(p= 0.002). At 24 months post-transplant, the recovery rate
of total CD4+ T cells was slower than that of total CD8+ cells
(p= 0.01), but there was no difference in the magnitude of
recovery of naı¨ve versus memory cells (p= 0.740). Of note,
the recovery of TEM cells was nearly twice that of TCM cells,
which is suggestive of an increased risk of late acute
rejection (4). Interestingly, similar to the findings of Pearl
et al., who studied an adult population, Serres found that
children have an increased regulatory T-cell to TEM ratio
in vivo, which may be tolerogenic (4,9). The percentage of
children with circulating antibodies over the 2 years of
the study was 23%, 50% of whom developed antibodies
between 12 and 24 months (4).
Few studies exist on the use of alemtuzumab in children.
Retrospective, small case studies have revealed equal
efficacy between alemtuzimab induction and other induc-
tion agents, such as daclizumab and ThymoglobulinH, based
on one-year actuarial patient and graft survival and
renal function (5,10). Tan et al. retrospectively reviewed 42
consecutive living donor kidney transplantations performed
over 4 years, in which the recipients received alemtuzumab
prior to graft revascularization followed by tacrolimus
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monotherapy with spaced weaning. Of the 42 living donor
transplants, 13 underwent transplant biopsies for a rising
serum creatinine from baseline, and only 2 patients (4.8%)
were diagnosed with acute cellular rejection (ACR). Every
three months, the recipients were screened for anti-HLA
antibodies and donor-specific antibodies were identified and
characterized by Luminex assays. None of the patients in this
study developed antibody-mediated rejection (AMR) (6).
There are certain settings in kidney transplantation where
alemtuzumab may not necessarily be the ideal induction
agent. In a small case series of complicated pediatric kidney
transplant cases described by Bartosh and colleagues,
alemtuzumab was associated with higher rates of rejection
(11). In addition, the use of alemtuzumab may be proble-
matic in kidney transplantations following a liver trans-
plant in a hepatitis C virus-positive recipient or a recently
transplanted patient who received heavy immunosuppres-
sion for the nonrenal organ, as this can be associated with
higher rates of infection and a possible increased risk of
post-transplant lymphoproliferative disorder (PTLD) (3).
& SIROLIMUS
The introduction of cyclosporine in the 1980s dramatically
transformed the field of transplantation. The success of
calcineurin inhibitor (CNI)-based immunosuppression, how-
ever, is limited by nephrotoxicity. This limitation has led to
an interest in CNI-free immunosuppressive regimens, but
a solution remains elusive. Children with end-stage liver,
intestinal, lung, and heart diseases are able to undergo organ
transplantation, but the long-term consequences following
non-renal solid organ transplantation include chronic kidney
disease, end-stage renal disease, and the need for future
kidney transplantation (12). The withdrawal of CNIs after a
period of time after transplantation and conversion to CNI-
free regimens have been attempted with mixed results (13-
15). In recent years, there have been promising new agents
that have become available for clinical use.
Sirolimus is a macrolide compound derived from
Actinomyces hygroscopicus. It is structurally similar to
tacrolimus and was introduced for clinical use in organ
transplantation in 1999 (16). Sirolimus binds to the
Figure 1 - Site of Action for Common Immunosuppression Agents in Cell Cycle. The mitotic phase (M) includes prophase, metaphase,
anaphase, and telophase. G1 is the first growth phase and includes growth and normal metabolic roles. The synthesis phase (S) is
responsible for DNA replication. The second growth phase (G2) includes growth and preparation for mitosis. Sirolimus and everolimus
inhibit the cell cycle at the G1 phase, while FK778 inhibits the cell cycle early in the S phase. MMF, azathioprine, and cyclophosphamide
directly inhibit nucleotide synthesis in the S phase.
Table 1 - Bortezomib Protocols for the Treatment of Antibody-Mediated Rejection.
Authors Day Bortezomib AMR Protocol
Morrow et al.
(heart) (44)
1
1,4,7,11
14-16
18
Follow-up after 30 days
Rituximab 375 mg/m2 IV
Plasmapheresis, Methylprednisolone (5 mg/kg), bortezomib (1.3 mg/m2 IV)
Plasmapheresis
PRA
DSA, T/B cell subsets
Cincinnati
(kidney, pancreas,
intestines,
heart) (40)
1
1,4, 8, 11, and 14
16-19 or
16-21
Rituximab (375 mg/m2)
Plasmapheresis (1.5 plasma volume), bortezomib (1.3 mg/m2), DSA. Biopsy at 8 and 14
Plasmapheresis (1.5x plasma volume) daily, DSA day 19
Plasmapheresis (1.5x plasma volume) every other day, DSA day 21
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mammalian target of rapamycin (mTOR) in T cells,
suppressing T-cell proliferation by inhibiting the progres-
sion from the G1 to S phase of the cell cycle. Sirolimus
allows T cell activation but prevents the cells from
proliferating in response to IL-2, which inhibits growth
factor-induced proliferation of lymphocytes and cells of
mesenchymal origin. Sirolimus has anti-proliferative effects
on fibroblasts, endothelial cells, and smooth muscle cells
that make it a promising agent for the prevention of chronic
allograft nephropathy and the progression of kidney disease
in non-renal solid organ transplantation (15,17-23).
Sirolimus is a hydrophobic agent that has rapid bioavail-
ability. Variable effects can occur depending on food
consumption, with oral suspension bioavailability decreas-
ing with high-fat meals but increasing if tablets are
administered. It is metabolized by the cytochrome P450
3A isoenzyme in the intestinal wall and liver. The half-life of
sirolimus in adult renal transplant patients is 62¡16 hours,
but small trials have demonstrated more rapid clearance in
younger children (16,24).
The most common side effects of sirolimus are dose-
related and include hyperlipidemia and a variety of
cytopenias. Interstitial lung disease and mouth ulcers have
also been reported in adult and pediatric patients treated
with sirolimus. Although sirolimus is not generally thought
to be nephrotoxic, it can be associated with proteinuria,
which can lead to nephrotic syndrome and subsequent
kidney injury (25).
The use of sirolimus in children has not been well
described, with most of the available clinical information
originating from single-center case studies. Many groups are
attempting CNI minimization and avoidance protocols with
mTOR inhibitors, such as everolimus or sirolimus, to prevent
post-transplant CKD. Chinnock and colleagues minimized
CNI exposure by adding sirolimus to the immunosuppres-
sion protocol when pediatric heart transplant recipients
developed renal insufficiency (GFR,60 mL/min/1.73 m2)
and found that renal function improved or stabilized
following CNI minimization (20). Hynes and colleagues
examined the use of sirolimus-based calcineurin inhibitor-
free immunosuppression in renal transplantation. They
found that sirolimus-based immunosuppression could be
successfully used in low-risk patients and first-time trans-
plant recipients without histological evidence of acute
rejection on a three-month surveillance biopsy. After five
years, they found that apthous ulcers and BK virus viremia
were the most prevalent adverse events (26). The role of
sirolimus in CNIminimization is also being explored in other
solid organ transplantations. Gibelli and colleagues found
that conversion from CNI to sirolimus was safe, with no
increased rates of rejection following pediatric liver trans-
plantation (21).
Figure 2 - Site of Action of Newer Agents Used in Treatment of Antibody Mediated Rejection (39). Abatacept, belatacept, and
alemtuzimab inhibit binding at the sites of T and B cells. IVIG, plasmapheresis, and rituximab affect the plasma cells.
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& EVEROLIMUS
Everolimus is a macrocyclic lactone that was first isolated
from Streptomyces hygroscoicus. It is a derivative of sirolimus
and shares its mechanism of action. The advantages of
everolimus are that it is more hydrophilic, demonstrating a
shorter half-life of approximately 30 hours, and has greater
bioavailability compared with sirolimus. Everolimus is
metabolized by the cytochrome 450 3A isoenzymes and,
similar to sirolimus, is also affected by dietary changes (16).
Based on experimental animal models and experience in
cardiac transplantation, everolimus also appears to have
antiproliferative effects on vascular smooth muscle cells and
fibroblasts (16,27). The antiproliferative action of everolimus
in the arterial wall has been shown to inhibit atherogenic
and intimal wall remodeling in pre-clinical studies. It is also
involved in a critical part of the cell cycle that has significant
antineoplastic potential as a promoter of apoptosis and
inhibitor of angiogenesis (28).
Ettenger and colleagues used a CNI minimization proto-
col comprising everolimus, cyclosporine, and corticoster-
oids following kidney transplantation. Of the 19 pediatric
patients enrolled, 15 were followed for 3 years. The patient
survival rate was 100%, and the allograft survival rate was
93%. Three patients had infectious complications, 4 patients
developed rejection, 4 patients required treatment with
statins for hypercholesterolemia, and the average serum
creatinine was 1.1 mg/dL after 3 years (29). Another
prospective study examined 20 children who received
basiliximab, cyclosporine A, and prednisolone for immu-
nosuppression. Two weeks following kidney transplanta-
tion, everolimus was initiated and cyclosporine A was
reduced by 50%. Pape and colleagues found that the mean
GFR at 1 and 3 years was 71 and 61 mL/min/1.73 m2,
respectively. There were no cases of post-transplant
lymphoproliferative disorder, acute rejection, or polyoma
nephropathy, and 85% of the patients remained on the
original immunosuppressive regimen (30).
Although only limited pediatric studies have been
performed to evaluate the efficacy of everolimus in liver
and heart transplantation, the early adult data are promis-
ing. A study in pediatric heart transplant recipients showed
that conversion to CNI-free immunosuppression with ever-
olimus and mycophenolate when the GFR fell below
75 mL/min/1.73 m2 resulted in improved renal function
within 6 months of CNI withdrawal in pediatric heart
transplant recipients (31). The possible benefit of the anti-
fibrotic effects of everolimus, as well as its lack of
nephrotoxicity, make it a promising immunosuppressive
agent in pediatric transplantation (28).
& BELATACEPT
Belatacept is a biological agent that is a selective co-
stimulation blocker of T cells. It is a fully human fusion
protein of the CTLA4 extracellular domain with fragments
of the Tc domain of human IgG1, and it has a binding
affinity to CD86/CD80 on the antigen-presenting cell, thus
resulting in the blockade of T-cell activation (32,33). The
activation of T cells involves the presentation of a peptide by
an antigen-presenting cell to the T cell receptor, followed by
costimulatory associations between the ligands on the
antigen-presenting cell and T cell receptors (33). In addition,
belatacept indirectly inhibits antigen-specific antibody (IgG,
IgM, and IgA) production by B lymphocytes, resulting in
lower mean immunoglobulin concentrations compared
with that resulting from cyclosporine-based therapy (32).
Belatacept requires intravenous infusion, and the total
infusion dose is based on the body weight of the patient. A
dose of 10 mg/kg is administered on the day of transplanta-
tion, day 5, and at 2, 4, 8, and 12 weeks, followed by 5 mg/kg
at the end of week 16 and every 4 weeks thereafter for
maintenance (32,34).
The BENEFIT trial has resulted in the publication of data
on adult kidney transplant recipients, including three year
outcome data. BENEFIT was a randomized, three-year,
phase III study in adults receiving either a standard
deceased or living donor kidney transplant. The patients
were randomized to a more intense regimen (MI), a less
intense regimen (LI), or cyclosporine. Of the 666 patients
who completed at least 3 years of therapy, 92% of the MI,
92% of the LI, and 89% of the cyclosporine patients survived
with a functioning allograft. At 3 years, the average
calculated GFR was 21 mL/min/1.73 m2 higher in the
belatacept group compared with the cyclosporine group.
This difference in GFR between the belatacept and
cyclosporine groups was enough to classify the mean GFR
as stage II (65 mL/min/1.73 m2) verses stage III (44 mL/
min/1.73 m2) chronic kidney disease. Overall, stage II or
better chronic kidney disease represented 69% of the MI,
71% of the LI, and only 29% of the cyclosporine-based
treatment groups at 3 years. In addition to improved renal
function, donor-specific antibodies occurred in 6% of MI, 5%
of LI, and 11% of the cyclosporine treatment arms. The
cumulative rates of acute rejection were 24% in the MI, 17%
in the LI, and 10% in the cyclosporine group at year 3.
Despite an early increased occurrence of acute rejection and
post-transplant proliferative disorder, especially in EBV
seronegative patients, belatacept-treated patients main-
tained a comparable rate of patient and graft survival with
cyclosporine but had better renal function (35).
To date, clinical trials using belatacept have been
conducted exclusively in adult patients, and no clinical
trials in children have been listed through the National
Institute of Health (36). Abatacept is a first-generation
biological agent with a similar mechanism of action to
belatacept, but it is used in patients with autoimmune
disorders and not transplant patients. The pharmacokinetics
of either abatacept or belatacept have not been studied
specifically in children or adolescents. The efficacy of
abatacept in the treatment of juvenile rheumatoid arthritis
was studied by the Pediatric Rheumatology International
Trials Organization and the Pediatric Rheumatology
Collaborative Study Group in a population with ages
ranging from 6-17 years. The trial was a randomized,
double-blind, placebo-controlled withdrawal study that was
performed at 45 centers in Europe and the United States
between 2004 and 2006 and enrolled 190 patients. Several
adverse events were documented, including a total of 95
infections in the open-label, lead-in, and controlled with-
drawal phases and 1 serious infection secondary to varicella
zoster. In the open-label, long-term extension phase span-
ning an average of 35 months, there were 6 serious
infections, including dengue fever, erysipelas, gastroenter-
itis, herpes zoster, bacterial meningitis, and pyelonephritis.
EBV or CMV disease was not mentioned (37). In 2009,
the United States Food and Drug Administration (FDA)
examined the 5-year post-marketing data of 90 patients
treated with abatacept. Six serious adverse events were
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reported, four of which occurred in the United States. One
case of multiple sclerosis (MS) and lymphoma occurred one
month after starting abatacept, and the other serious events
included skin infection, dyspnea, purpura, and transamini-
tis. The child who developed MS also developed temporal
lobe epilepsy 19 months after starting abatacept for the
treatment of JIA. He was also on methotrexate and
ondansetron, which have been associated with the devel-
opment of epilepsy. The child who developed lymphoma
initially developed lymphomatoid papulosis 1 month after
starting abatacept for vasculitis and had been on immuno-
suppressive therapy for 10 years (38).
Although belatacept has not been used in pediatric
transplantation, it may have a role in the future. The method
of administration may positively affect rates of medication
administration non-compliance, which is a particular problem
in adolescent and young adult transplant management. The
higher rates of PTLD were concentrated in patients who were
seronegative for Epstein-Bar virus (EBV) and those who were
in the MI arm (35). This may be problematic for the extension
of belatacept in pediatric patients, as many of these patients
are seronegative for EBV at the time of transplantation.
& BORTEZOMIB
Historically, T-cell-mediated mechanisms have been
considered to be the main cause of allograft rejection.
However, the role of humoral responses, particularly those
mediated by alloantibodies, has increasingly being impli-
cated in allograft rejection (39). As antibody-mediated
rejection (AMR) has gained recognition, so has the realiza-
tion that traditional therapies for AMR, including IVIG,
plasmapheresis, rituximab, and antilymphocyte prepara-
tions, are inconsistent in efficacy (40).
Bortezomib is a proteasome inhibitor. The 26S proteasome
is the site of degradation of nearly all intracellular proteins.
Damaged and misfolded proteins, as well as proteins
targeted for degradation, are all degraded in the protea-
some. Proteasome inhibition induces endoplasmic reticu-
lum (ER) stress, unfolded protein response (UPR), and
terminal UPR. The UPR involves the inhibition of transla-
tion and, therefore, immunoglobulin production, and it
also increases the cellular capacity to repair misfolded or
unfolded proteins. Proteasome inhibition also induces
programmed cell death by cell cycle arrest in cells under-
going mitosis at specific checkpoints (40). In vivo studies
have demonstrated that proteasome inhibitors can result
in the deletion of non-transformed plasma cells, which
manufacture alloantibodies (40).
Bortezomib is approved by the FDA for the treatment
of multiple myeloma (40). A variety of protocols exist for
treatment of AMR with boretzomib, and examples are listed
in Table 1. In transplant patients, it was initially studied
for the treatment of refractory AMR. Bortezomib has been
demonstrated to reduce donor-specific antibodies in both
heart and kidney transplant patients (40-42). Everly and
colleagues used bortezomib to treat patients with refractory
renal allograft rejection and found that bortezomib therapy
was associated with improved renal function and renal
allograft histology, as well as reductions in DSA levels. To
remove circulating antibodies, plasmapheresis is necessary
in addition to bortezomib administration (40,43). Utilizing
rituximab at the start of treatment was found to reduce
plasma cell antibody production prior to depletion with
bortezomib (40). Morrow and colleagues treated four
pediatric heart transplant patients with refractory AMR,
who had failed plasmapheresis, intravenous immunoglo-
bulin, and rituximab, with intravenous bortezomib, ritux-
imab, and plasmapheresis. The patients had improved
systolic function, and conversion to C4d-negative biopsies
was observed in 75% of patients. Additionally, 25% of
patients became IgG-negative and had a prompt and
precipitous reduction in DSAs (44). Although studies have
demonstrated the effectiveness of bortezomib, there are
several case reports and small case studies that revealed
bortezomib to be ineffective in prolonging graft survival,
despite decreasing the DSA load, in prolonged or refractory
AMR (45,46).
The University of Cincinnati developed a collaborative
study group of transplant centers, the START collaboration,
and has studied the use of bortezomib in over 91 solid organ
transplants with 107 episodes of AMR. The experience
included both adult and pediatric kidney, pancreas, and
intestinal, as well as pediatric and adult heart, transplant
recipients. Bortezomib provided effective treatment in all
types of solid organ transplants studied (40).
& ECULIZUMAB
Atypical hemolytic uremic syndrome (aHUS) is a disease
of the microvasculature characterized by hemolytic anemia,
thrombocytopenia, and acute kidney injury, with more
than 50% of patients progressing to end-stage renal disease
(ESRD) (47,48). The diagnosis of aHUS is made based on a
lack of associated disease, criteria for Shigatoxin-HUS, and
criteria for thrombotic thrombocytopenic purpura (TTP),
with serum ADAMTS 13 activity .10%. Onset can vary
from infancy to adulthood. Additionally, 2-10% die, 1/3
progress to ESRD after the first episode, and 50% of the
patients have relapses. There is a high risk of post-
transplant recurrence, except in the setting of membrane
cofactor protein disease, in which case most patients have
preserved renal function. The most frequent mutations are
located in complement factor H (CFH), and the disease
recurs in nearly 80% of patients transplanted with CFH
mutations (47,49).
The known pathogenesis of aHUS is primarily related to
the dysregulation of the complement cascade. In approxi-
mately 50% of affected patients, mutations in genes
encoding complement proteins result in impaired regula-
tion of the complement alternative pathway, leading to
inappropriate complement activation in platelets and
endothelial cells, primarily within the kidney (50). Until
recently, renal transplantation alone has not been an
effective treatment option for aHUS patients because of
high morbidity and mortality rates primarily associated
with disease recurrence and premature liver failure second-
ary to uncontrolled complement activation (48,50). Several
combined liver-kidney transplants have been performed
with the goal to have the transplanted liver supply normal
complement regulatory proteins in patients with aHUS.
However, this approach does not address the problem in
patients with CFH autoantibodies (48,51-54).
Kidney transplantation markedly activates the alternative
pathway of the complement system, resulting in a poor
outcome in aHUS patients with mutations in FH (50). The
identification of anticomplement therapy has led to a safer
approach than kidney transplantation alone. Eculizumab is
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a complete, humanized C5 monoclonal antibody that
inhibits complement factor 5a, blocking terminal comple-
ment activation and the formation of membrane attack
complexes (48-50). The prophylactic use of eculizumab and
plasmapheresis in kidney transplant recipients with aHUS
has demonstrated favorable outcomes in several case
reports involving genetic defects, including CFH, C3,
complement factor H-related proteins (CFHR1 and CFH
hybrids) (48,50,55-57).
There is also growing interest in using eculizumab to
prevent complement-mediated injury in kidney transplan-
tation, ranging from use in the positive cross-match donor
to prevention of antibody-mediated rejection in sensitized
recipients to the prevention of delayed graft function in
deceased donors. Currently, several adult studies are
actively recruiting participants (36). Eculizumab was used
as a rescue treatment for severe AMR or prevention of
AMR. Early results from the Mayo Clinic showed that
eculizumab prevents the development of acute AMR in
cross-match-positive patients. Eculizumab was added to the
desensitization protocol with mixed results. One of 16
patients developed AMR, and 6 patients developed chronic
AMR by 3.8 months post-transplantation (58-60).
& FK778
FK778 (manitimus) is a synthetic malononitrilamide
derivative of the active leflunomide metabolite, terifluno-
mide, which has been demonstrated to have both immuno-
suppressive and anti-proliferative activities. It inhibits both
T-cell and B-cell functions by blocking de novo pyrimidine
synthesis, inhibiting tyrosine kinase activity, and suppres-
sing IgG and IgM antibody production, as shown both
in vitro and in vivo (16,61). In addition, FK778 prevents
vascular remodeling after intimal injury and blocks the
replication of the herpes virus family in vitro (16). Animal
studies examining the role of FK778 in liver regeneration
and acute rejection have been carried out in rats that
underwent segmental liver transplantation. FK778 was
found to be antihepatotrophic and antiproliferative in rat
liver regeneration (62). FK778 was also found to prevent
acute allograft rejection and reverse ongoing rejection in
rats undergoing liver, heart, or kidney transplantation.
Combination therapy with tacrolimus was also found to be
more beneficial than FK778 monotherapy (63,64).
A phase II, multi-center, randomized, double-blind study
compared FK778 with tacroilmus and steroids verses MMF
with tacrolimus and steroids in renal transplantation
patients and found that at low levels, FK778 and MMF
had similar efficacy (61). Unfortunately, as there were not
sufficiently good results to justify phase III studies of FK778,
this agent is not being further developed.
& JAK3 INHIBITORS
The Janus kinase family is a group of four cytoplasmic, non-
receptor tyrosine kinases. JAK3 is highly expressed in
lymphoid cells and is activated only by cytokines that bind
to gamma chain-containing receptors. It is a potential
immunosuppressive target because JAK3 activation leads to
the dimerization of the STAT 5 transcription factor, which is
specific for IL-2 cytokines. JAK3 controls various cytokine-
regulated signal transduction pathways, including lymphocyte
proliferation, differentiation, and apoptosis (65). Concerns
regarding JAK3 inhibition exist because the loss of NK
cells may lead to impaired innate immunity and memory.
Additionally, as it is very similar to JAK2, which mediates
signaling of hematopoiesis, its inhibition could potentially lead
to anemia, leukopenia, and thrombocytopenia (16).
CP-690550, tofacitinib, is an oral JAK3 inhibitor with the
potential to prevent transplant rejection and treat auto-
immune diseases. Phase I and II clinical trials have
demonstrated that tofacitinib is efficacious and safe in
preventing organ transplant rejection (66). In a phase 2b
trial, tofacitinib was equivalent to cyclosporine in prevent-
ing acute rejection and was associated with improved renal
function and less chronic allograft disease. At the dose
studied, tofacitinib caused side effects, and adverse events
occurred in over 10% of the treatment group. Adverse
events included serious infection and CMV disease, post-
transplant proliferative disorder, anemia, and neutropenia.
One anticipated challenge will be the monitoring of drug
levels, and a decision has not yet been made to start phase
III trials.
& FTY 720
FTY720, fingolimod, is derived from a fungal sphingosine-
like metabolite. It is a sphingosine 1-phosphate receptor
modulator that is able to entrap lymphocytes in secondary
lymphoid organs, thus reducing their availability for cell-
mediated immune responses in allografts (16,67). Fingolimod
use has been associated with bradycardia, macular edema,
and increased airway resistance. Additionally, when com-
bined with tacrolimus, it did not demonstrate a significant
therapeutic advantage over MMF in preventing acute
rejection in kidney transplant recipients (16,68). Although it
has not moved forward in the treatment of transplant
recipients, it may have a role in treating patients with
autoimmune diseases.
& ALEFACEPT
Alefacept, LFA-3-Ig, is a dimeric fusion protein consisting
of the CD2-binding portion of the human lymphocyte
function-associated antigen-3 (LFA-3) linked to the Fc
portion of human IgG1. It is thought to neutralize the effect
of CD2-expressing T-cells by complement-mediated lysis,
interrupt the CD2 interaction with LFA-3, limit helper T-cell
adhesion to antigen-presenting cells, and disrupt effector
T-cell receptor engagement with antigens and major histo-
compatibility complexmolecules (69). A pilot study assessing
the safety and efficacy of alefacept in de novo kidney
transplant recipients was terminated because of increased
risks that were greater than expected based on the standard
of care. However, alefacept is currently undergoing clinical
trials for the prevention of graft versus host disease (16,36).
& ASKP1240
ASKP1240 is a novel, human anti-CD40 monoclonal
antibody that is currently in pre-clinical trials as a new
immunosuppressive agent that may promote tolerance
induction in organ transplantation. ASKP1240 has been
demonstrated to prolong renal allograft survival in non-
human primates (NHPs), although the allografts eventually
underwent chronic allograft nephropathy. Oura and collea-
gues completed a two-week ASKP1240 induction treatment
in NHPs and found that although it prolonged liver
allograft survival, the function of the graft deteriorated
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due to chronic rejection. Following a six-month ASKP1240
maintenance monotherapy protocol, cellular and humoral
alloimmune responses were suppressed, rejection was
prevented, and no serious side effects were observed in
hepatic allograft recipients (70).
A clinical trial assessing the bioavailability of ASKP1240
in healthy subjects after intravenous and subcutaneous
administration was recently completed in September 2012
and demonstrated that ASKP1240 was well tolerated in the
range of 50 to 500 mg, with no evidence of cytokine release
syndrome or thromboembolic events. There was no differ-
ence in the incidence of infection based on dose, but B
cell CD40 receptor occupancy trended to be prolonged as
the dose increased (71). Phase II trials are currently in
development (36).
& CMX001
CMX001 is a novel, broad-spectrum lipid antiviral con-
jugate that produces high levels of the active antiviral agent
cidofovir diphosphate and is active against multiple double-
stranded DNA viruses, such as JC and BK viruses (72). It
is a lipid conjugate of the acyclic nucleotide phosphonate
cidofovir. The utility of cidofovir is limited by the high
incidence of acute kidney toxicity and intravenous adminis-
tration. Compared to cidofovir, CMX001 has greater potency
in vitro against all double stranded DNA viruses that cause
human disease, a higher genetic barrier to resistance, no
evidence of nephrotoxicity in humans or animals, and is
available as an oral agent (73).
Painter and colleagues conducted a randomized, double-
blind, placebo-controlled, parallel-group, dose-escalation
study in healthy volunteers to examine the pharmacoki-
netics and safety of CMX001. They found that CMX001 is
orally bioavailable and well tolerated in healthy volunteers
at doses of up to 2 mg/kg, which corresponds to approxi-
mately 140 mg in a typical adult (72). BKV is associated with
nephropathy, as well as hemorrhagic cystistis (74). Treating
polyomavirus BK (BKV) is of notable importance in kidney
transplant recipients, as current agents, with the exception
of immunosuppressive reduction, which places transplant
recipients at increased risk for rejection, have not been
consistently effective in reducing BK viral loads. Com-
parisons of CMX001 and cidofovir have demonstrated that
CMX001 had more rapid and enduring effects on BKV DNA
than cidofovir at lower levels and had fewer side effects on
relevant host cells in vitro (74). No human studies in
transplant recipients with BK nephropathy or viremia have
been published to date, although an anti-viral agent against
BKV without associated nephrotoxicity is promising and
could positively impact the management of BKV.
& CONCLUSION
Despite the advances in immunosuppressive therapy, the
optimal immunosuppressive regimen remains elusive. Over
the years, research in immunosuppressive therapy has
intensified, and several promising agents targeting different
sites of the immune system are under development.
Important goals in finding new agents include reducing
nephrotoxicity; preserving both short- and long-term graft
function; and reducing the risk of opportunistic infections,
PTLD, malignancy, and other side effects. These goals are
particularly critical in pediatric transplant recipients due to
their life expectancy and the need to prevent additional
chronic medical conditions.
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